Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 20/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | TDO2 | P48775 | 1/20 | 0.56 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18483667 | 1.00 | IDO1 (0.56) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL144289 | 1.00 | IDO1 (0.56) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL144290 | 1.00 | IDO1 (0.56) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL146814 | 0.95 | IDO1 (0.50) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL15988481 | 0.95 | IDO1 (0.50) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL146815 | 0.95 | IDO1 (0.50) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL19465734 | 0.91 | IDO1 (0.56) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL30449662 | 0.91 | IDO1 (0.56) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL144773 | 0.91 | IDO1 (0.56) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL144772 | 0.91 | IDO1 (0.56) | IDO1CYP3A4CYP2C9TDO2IDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4190335-A1 | IMMUNOTHERAPY METHODS AND COMPOSITIONS INVOLVING TRYPTOPHAN METABOLIC PATHWAY MODULATORS | Juno Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | claimed |
| EP-3525803-B1 | IMMUNOTHERAPY METHODS AND COMPOSITIONS INVOLVING TRYPTOPHAN METABOLIC PATHWAY MODULATORS | JUNO THERAPEUTICS INC (US) | 2022-12-07 | — | — | EP | claimed |
| US-11896615-B2 | Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators | JUNO THERAPEUTICS, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| EP-4190335-A1 | IMMUNOTHERAPY METHODS AND COMPOSITIONS INVOLVING TRYPTOPHAN METABOLIC PATHWAY MODULATORS | Juno Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-3525803-B1 | IMMUNOTHERAPY METHODS AND COMPOSITIONS INVOLVING TRYPTOPHAN METABOLIC PATHWAY MODULATORS | JUNO THERAPEUTICS INC (US) | 2022-12-07 | — | — | EP | disclosed |
| US-20220323558-A1 | CANCER VACCINES | PFIZER INC. (US) | 2022-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11896615-B2 | Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators | KYNU, IDO1, IDO2 | IDO1 2/4885CYP3A4 1445/4885CYP2C9 991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.